Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0007097 (carcinoma)
 152,788 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The immunohistochemical determination of the accessory protein of DNA-polymerase delta (PCNA), a marker of an early S-phase of the cell cycle, was used to evaluate cell proliferation retrospectively in formalin-fixed, paraffin-embedded liver biopsy sections in a group of patients with cirrhosis of similar age and duration of follow up, and with no evidence of hepatocellular carcinoma (41), including 17 patients with and 24 without hepatocellular carcinoma appearance during follow up. Proliferation was expressed as total (PCNA-TOT) and strongly (PCNA-STRO) positive nuclei per 1000 hepatocytes. The presence of dysplasia was also recorded. Histological findings and biochemical data, at the time of liver biopsy, were compared in the two groups. While total PCNA positivities were not significantly different in the two groups, strong reactivity was significantly higher in patients who eventually developed hepato-cellular carcinoma (median 0.7 vs 2.6). Univariate analysis of histological and biochemical data at the time of biopsy, followed by a stepwise regression study, showed that the significant parameters for a time-dependent disease-free state were, in decreasing order: cholesterol, PCNA-STRO, PCNA-TOT and alpha foeto-protein. Other clinical, biochemical and histological parameters, including dysplasia, provided no further information. From these data, hepatocellular proliferation can be evaluated in patients with cirrhosis with a currently available technique. Patients with high cell proliferation are at increased risk of developing hepatocellular carcinoma and may require differentiated follow up.
 ...
PMID:Increased risk of hepatocellular carcinoma development in patients with cirrhosis and with high hepatocellular proliferation. 791 17

It has been proposed that immunostaining with PC10, a monoclonal antibody against proliferating cell nuclear antigen (PCNA), is of prognostic value in gastric carcinoma. Gastric carcinomas from a series of 90 patients in whom survival data were known have been studied. There was no relation between the degree of PC10 immunostaining assessed semiquantitatively and survival.
 ...
PMID:Expression of proliferating cell nuclear antigen (PCNA) in gastric carcinoma: no evidence for prognostic value. 791 1

The aim of this study is to evaluate the proliferating activity of ameloblastomas and its correlation to the biological behaviour according to each histological type. 38 cases of solid and unicystic ameloblastomas were reviewed including 1 case of ameloblastic carcinoma and 1 recurrent case. An anti-PCNA antibody, PC10(Dako), was applied for the detection of proliferating cell nuclear antigen (PCNA) in paraffin embedded tissue sections. Also 20 cases of dentigerous cysts were reviewed. In conclusion, we observed that there was no difference between the proliferating activities of the different histological types of solid ameloblastomas. Because 1 case of ameloblastic carcinoma and one recurrent case revealed remarkably high PCNA reactivity, we believe that PCNA would be useful in showing the differentiation between benign and malignant ameloblastomas. In unicystic ameloblastomas, plexiform intraluminal growth was considered to be an important feature in tumorous transformation of cystic epithelium.
 ...
PMID:Immunohistochemical study on proliferating cell nuclear antigen expression in ameloblastomas. 791 62

An immunohistochemical study of thyroid carcinoma using PC10, a monoclonal antibody against proliferating cell nuclear antigen (PCNA/Cyclin), was performed on paraffin sections. There was significant difference statistically in PCNA index between any two types of all four types of thyroid carcinoma (P < 0.01), with the index of 35.36 +/- 9.59 in papillary carcinoma, 184.60 +/- 7.08 in follicular carcinoma, 392.43 +/- 31.66 in medullary carcinoma, and 488.28 +/- 19.93 in undifferentiated carcinoma. The results indicate that PCNA/Cyclin detection is a reliable method to examine the fraction of proliferating cells of thyroid carcinoma on paraffin sections, and it could be used to determine the prognosis of thyroid carcinoma.
 ...
PMID:[Proliferating cell nuclear antigen/cyclin (PCNA/Cyclin) in thyroid carcinoma]. 791 37

Blood vessel invasion, recurrence rate, and time to recurrence were examined in relation to the immunohistochemical expression of proliferating cell nuclear antigen, sialyl LewisX, and sialyl Lewis(a) in 303 patients with lung cancer who had a curative resection from 1980 to 1991. Of these, 150 had adenocarcinoma, 117 had squamous, 21 had large-cell, and 15 had small-cell carcinoma. Significant differences were detected in the expression of proliferating cell nuclear antigen and sialyl LewisX between adenocarcinomas and the other histologic types; thus the subjects were divided into 150 with adenocarcinoma and 153 with non-adenocarcinoma. In those with adenocarcinoma, the frequency of blood vessel invasion was significantly higher in tumors with strong sialyl LewisX expression, and the disease-free survival of the patients with blood vessel invasion was significantly worse when their tumors strongly expressed both sialyl LewisX and proliferating cell nuclear antigen. In those with non-adenocarcinoma, on the other hand, tumors with strong expression of sialyl Lewis(a) and proliferating cell nuclear antigen showed significantly higher frequencies of blood vessel invasion and worse disease-free survival. In patients with recurrent tumors, those with strong proliferating cell nuclear antigen expression showed a significantly shorter time to recurrence. We conclude that sialyl LewisX and proliferating cell nuclear antigen expression in adenocarcinoma and sialyl Lewis(a) and proliferating cell nuclear antigen expression in non-adenocarcinoma may be an important determinant of recurrence.
 ...
PMID:Relation between recurrence and expression of proliferating cell nuclear antigen, sialyl LewisX, and sialyl Lewis(a) in lung cancer. 791 34

Abnormalities of p53, a known tumor suppressor gene, has been detected in various human malignant neoplasms. In this study, we analyzed immunohistochemically the localization of p53 using three different antibodies, PAb1801, DO-7, and CM-1 in 49 patients with esophageal squamous cell carcinoma. We compared the expression of p53 with the clinicopathological features, proliferating cell nuclear antigen (PCNA), and DNA ploidy. In addition, we performed flow cytometric analysis of p53 using DO-7 in 33 cases in order to evaluate the correlation between p53 overexpression and DNA ploidy simultaneously. By immunohistochemistry, immunoreactive p53 was observed in the nuclei of carcinoma cells in 29 cases (59%). Relatively larger diameter tumors (more than 5cm), poorly differentiated tumors, tumors with distant lymph node metastasis, and DNA aneuploidy tumors were positive for p53 more frequently. p53-positive cases had a higher PCNA labeling index and a poorer prognosis than p53-negative cases. By two parameter flow cytometric analysis, p53 was detected in 16 cases (49%) and DNA aneuploidy was detected in 27 cases (82%). A higher p53-positive rate (15/27.56%) was observed in DNA aneuploidy cases than in DNA diploidy cases (1/6.17%). However, this difference was not statistically significant. The p53 results by immunohistochemistry and flow cytometry were the same in 25 out of 33 cases (76%). These results suggest the possible correlation between p53 abnormalities and DNA aneuploidy and that analysis of p53 protein is useful for prediction of clinical course in esophageal squamous cell carcinoma.
 ...
PMID:p53 overexpression in human esophageal carcinoma: a correlation with tumor DNA ploidy and two parameter flow cytometric study. 791 93

The proliferative activity of human gastric carcinoma was measured by means of in vitro incorporation of the thymidine analogue, 5-bromo-2'-deoxyuridine (BrdU), into the newly-synthesized DNA of fresh tumors and immunohistochemical staining of proliferating cell nuclear antigen (PCNA) using avidin-biotin peroxidase method. Eighty-two cases of surgically resected human gastric carcinomas consisting of 18 various histologic types were subjected to study. The mean BrdU labelling index (LI) and PCNA LI were 22.9% and 39.1%, respectively. The correlation between BrdU LI and PCNA LI was statistically significant (correlation coefficient mu = 0.61334, p = 0.0001). We concluded that immunohistochemical staining for PCNA may become a practical method instead of in vitro or in vivo BrdU labeling to assess the proliferation fraction of the gastric cancer patient.
 ...
PMID:Comparison of bromodeoxyuridine and proliferating cell nuclear antigen labeling in gastric carcinoma. 791 18

Bowen's disease and invasive squamous cell carcinoma arising in Bowen's disease (Bowen's carcinoma) were investigated immunohistochemically with regard to their expression of proliferating cell nuclear antigen (PCNA) and the Ki-67 antigen. Both proliferation-associated proteins were found in all layers of the tumours, and were present in nuclei of any size and shape. The nucleoli lacked PCNA immunoreactivity, but they expressed the Ki-67 antigen. The PCNA labelling index was 36.9 +/- 12.6% in Bowen's disease (n = 16), and 40.7 +/- 11.0% in Bowen's carcinoma (n = 3). The Ki-67 antigen labelling index was 43.6 +/- 16.7% in Bowen's disease (n = 16), and 51.7 +/- 11.6% in Bowen's carcinoma (n = 3). Dyskeratotic cells were positive for PCNA and the Ki-67 antigen, suggesting that these cells are not in a post-mitotic state. We conclude that in dyskeratotic cells of Bowen's disease the cell cycle is interrupted by nuclear disorganization.
 ...
PMID:Expression of proliferation-associated proteins (proliferating cell nuclear antigen and Ki-67 antigen) in Bowen's disease. 791 88

We tested the hypothesis that proliferating cell nuclear antigen can predict survival in patients with mucoepidermoid carcinoma. Formalin-fixed, paraffin-embedded, tissue resected specimens from 43 patients with no prior treatment for mucoepidermoid carcinoma of the parotid gland were immunostained with the PC10 monoclonal antibody to proliferating cell nuclear antigen with the peroxidase/antiperoxidase method. Proliferating cell nuclear antigen levels were defined as the number of nuclei with strong immunostaining divided by the total cell count and were expressed as percentages. Both univariate and multivariate analyses were performed on 12 additional prognostic variables to determine the relative proliferating cell nuclear antigen level to predict survival. The median proliferating cell nuclear antigen level was 7. Five percent of patients with proliferating cell nuclear antigen levels less than 7 died of their disease compared with 48% of those with proliferating cell nuclear antigen levels of 7 or more. Multivariate analysis indicates proliferating cell nuclear antigen to be the most important parameter in predicting survival. Thus the measurement of proliferating cell nuclear antigen is a useful predictor of survival for patients with mucoepidermoid carcinoma of the parotid gland.
 ...
PMID:High correlation with survival of proliferating cell nuclear antigen expression in mucoepidermoid carcinoma of the parotid gland. 793 79

Several recently developed techniques have been applied to the study of endometrial lesions. These include the evaluation of K-ras abnormalities in patients with endometrial hyperplasia to identify those at high risk to develop carcinoma, the analysis of p53 abnormalities to distinguish between endometrial hyperplasia and carcinoma, the use of p53 for predicting clinical outcome in patients with endometrial carcinoma, and PCNA immunostaining of endometrial lesions with secretory activity. However, these studies should be regarded at this juncture as auxiliary, at best, to the cytological and histopathologic examination of human endometrial disorders.
 ...
PMID:New concepts in the diagnosis and prognosis of endometrial carcinoma. 793 50


<< Previous 1 2 3 4 5 6 7 8 9 10